In January 2026, Utah became the first place in the United States where an AI system can legally renew drug prescriptions without a doctor signing off on each individual case. The company behind it is called Doctronic, founded in 2023 and based in New York.
The way it works is straightforward. A Utah resident logs on, confirms their identity, answers a short set of health questions, and the AI checks their prescription history through a national pharmacy database. If everything looks clear, the AI sends a refill straight to a local pharmacy. The cost is $4 per refill. If something looks complicated, the system passes the patient to a human doctor.
This was only possible because Utah created what it calls a regulatory sandbox: a formal program that lets the state temporarily set aside certain professional licensing laws so companies can test new technology under supervision. Doctronic signed a one-year agreement under that program. The list of eligible medications covers around 190 common maintenance drugs, things like blood pressure medication, cholesterol pills, antidepressants, and birth control. Controlled substances and injectables are excluded.
The problem is the program launched without the people who normally oversee medical licensing in Utah even knowing about it. The state's medical licensing board found out when the launch was reported in the news. Eleven board members wrote a letter in March 2026 asking for the program to be stopped, citing concerns about medications that become dangerous when a patient's health changes between visits. Blood thinners were specifically flagged. The board was told the program was happening and that they had no say.
As of April 2026, the program is still in its cautious first phase: every refill requires a human doctor to authorize it before it goes out. No serious safety incidents have been reported. But Doctronic plans to remove that human check and move to fully automated refills.
The federal picture is genuinely unclear. The US Food and Drug Administration, which normally oversees tools that affect medical decisions, has not approved any AI chatbot for medical use. Doctronic's executives declined to say whether they had even contacted the FDA. The FDA for its part said it has not authorized any AI chatbots but wants to encourage medical innovation. That is not a position, it is an absence of one.
Meanwhile, Doctronic raised $40 million in a Series B round in March 2026, bringing its total funding to $65 million across three rounds in under a year. The company says it has more than 300,000 weekly users and is on track to earn over $10 million in revenue this year. It is in active talks with regulators in other states to expand the prescription program.
Lawmakers in Iowa, Idaho, and other states are introducing legislation to formally license AI medical services. Many of those bills follow a template from a pro-AI think tank with ties to the co-founder of Palantir. Texas and Wyoming have already created their own AI sandbox programs. A bill in the US Congress called the Healthy Technology Act of 2025 would let AI systems be formally recognized as prescribing practitioners if states approve, but it has not made it out of committee.
The real issue here is not whether AI can handle routine prescription refills. There is a reasonable case that it can, at least for stable patients on well-understood medications. The issue is that no one has agreed on what standard an AI must meet before it is allowed to do this. Doctronic set its own benchmarks, persuaded a state office to accept them, and launched. That process would be concerning for a new restaurant, let alone a medical service.
For any business that manages employee health benefits, runs occupational health programs, or simply employs people in countries where AI medical services are expanding, this is the moment to start paying attention. The rules are being written right now, state by state, and whoever moves first is setting the standard everyone else will have to follow.